The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Advances in genomics, biotechnology, and biodetection, including major contributions to the complete sequencing of the human genome though the Joint Genome Institute and the development of rapid PCR (polymerase chain reaction) technology that lies at the heart of today's most advanced DNA detection instruments. Development and operation of the National Atmospheric Release Advisory Center (NARAC), which provides real-time, multi-scale (global, regional, local, urban) modeling of hazardous materials released into the atmosphere. Development of highest resolution global climate models and contributions to the Intergovernmental Panel on Climate Change which, together with former vice president Al Gore, was awarded the 2007 Nobel Peace Prize. Co-discoverers of new superheavy elements 113, 114, 115, 116, 117, and 118. Invention of new healthcare technologies, including a microelectrode array for construction of an artificial retina, a miniature glucose sensor for the treatment of diabetes, and a compact proton therapy system for radiation therapy. On July 17, 2009 LLNL announced that the Laboratory had received eight R&D 100 Awards – more than it had ever received in the annual competition. The previous LLNL record of seven awards was reached five times – in 1987, 1988, 1997, 1998 and 2006. Also known as the "Oscars of invention", the awards are given each year for the development of cutting-edge scientific and engineering technologies with commercial potential. The awards raise LLNL's total number of awards since 1978 to 129.
== Activity == Given its half-life, the radioactive activity of a gram of 60Co is close to 42 TBq (1,100 Ci). The absorbed dose constant, used in calculations of gamma-ray exposure, is related to the decay energy and time. For 60Co it is equal to 0.35 mSv/(GBq h) at one meter from the source. This allows calculation of the equivalent dose, which depends on distance and activity - for example, 2.8 GBq or 60 μg of 60Co, generates a dose of 1 mSv at 1 meter away, within an hour. Test sources, such as those used for school experiments, have an activity of <100 kBq. Devices for nondestructive material testing use sources with activities of 1 TBq and more. The decay energy of cobalt-60 amounts to about 26 watts per gram, about 40 times larger (by mass) than that of e.g. 238Pu but still not very significant for practical sources.
=== Cardiac === The apelin receptor is expressed early during the embryonic development of the heart, where it regulates the migration of cell progenitors fated to differentiate into cardiomyocytes, the contractile cells of the heart. Its expression is also detected in the cardiomyocytes of the adult where apelin behaves as one of the most potent stimulator of cardiac contractility. Aged apelin knockout mice develop progressive impairment of cardiac contractility. Apelin acts as a mediator of the cardiovascular control, including for blood pressure and blood flow. It is one of the most potent stimulators of cardiac contractility yet identified, and plays a role in cardiac tissue remodeling. Apelin levels are increased in left ventricles of patients with chronic heart failure and also in patients with chronic liver disease.
Sources: en.wikipedia.org
33 amino acids peptide (sequence GDCLPHLKRCKADNDCCGKKCKRRGTNAEKRCR, disulfide bonds Cys3-Cys17, Cys10-Cys21, Cys16-Cys32). the formula is C148H260N58O45S6. shares the structure and function of the dihydropiridine receptor (DHPR). It corresponds to the II-III loop of the α1s subunit. three cysteine residues that form disulfide bridges to stabilize the three-dimensional structure. The molecular weight of the toxin is 3.7 kDa. IpTxa acts on the Ryanodine receptors (RyR), which are intracellular Ca2+ release channels mainly known for their role in regulating Ca2+ release from the sarcoplasmatic reticulum of striated muscles. The peptide acts better on RyR type 1 than on type 3. RyR type 2 seems to be insensitive to IpTxa. The part of the peptide that looks like the II-III loop of the (DHPR) binds directly to RyR and enhances ryanodine binding to trigger Ca2+ release.
== Transport mechanisms == The transport of norepinephrine back into presynaptic cell is made possible by the cotransport with Na+ and Cl−. The sequential binding of the ions results in the eventual reuptake of norepinephrine. The ion gradients of Na+ and Cl− make this reuptake energetically favorable. The gradient is generated by the Na+/K+-ATPase which transports three sodium ions out and two potassium ions into the cell. NETs have conductances similar to those of ligand-gated ion channels. The expression of NET results in a leak-channel activity.
An interview with Francis Crick and Christof Koch, 2001 Archived 3 March 2009 at the Wayback Machine Listen to Francis Crick The Quest for Consciousness Archived 3 March 2009 at the Wayback Machine – The Quest for Consciousness – 65 minute audio program — a conversation on Consciousness with neurobiologist Francis Crick of the Salk Institute and neurobiologist Christof Koch from Caltech. Listen to Francis Crick and James Watson talking on the BBC in 1962, 1972, and 1974. The Impact of Linus Pauling on Molecular Biology – a 1995 talk delivered by Crick at Oregon State University About his work
Sources: en.wikipedia.org
== Extensions == FASTQ format is a form of FASTA format extended to indicate information related to sequencing. It is created by the Sanger Centre in Cambridge. A2M/A3M are a family of FASTA-derived formats used for sequence alignments. In A2M/A3M sequences, lowercase characters are taken to mean insertions, which are then indicated in the other sequences as the dot (".") character. The dots can be discarded for compactness without loss of information. As with typical FASTA files used in alignments, the gap ("-") is taken to mean exactly one position. A3M is similar to A2M, with the added rule that gaps aligned to insertions can too be discarded.
Antimicrobial activity – Citropten may exhibit antibacterial and antifungal properties. This characteristic could be relevant for applications in disinfectants or preservatives. Anti-inflammatory and antioxidant effects – Emerging research indicates citropten might have anti-inflammatory and antioxidant capabilities. These properties could hold promise for various health applications. The pleasant aroma of citropten makes it a valuable component in the fragrance industry, used in perfumes and cosmetics. Its potential antimicrobial properties are also prompting exploration for use in medicine and pharmaceuticals.
=== Behavior === Relatively little is known about appropriate behavioral expression for farmed species of insects. Adult black soldier flies are unlikely to be able to lek, a natural mating behavior, in most current cage sizes. Adult black soldier flies are unable to engage in natural foraging/feeding behaviors when not provided with feed. Photophobic insect larvae, or crickets of any life stage, may not be able to avoid or escape lights during some parts of rearing or processing. Selection, or genetic modification, could reduce the ability of insects to perform natural behaviors: for instance, one study genetically modified adult black soldier flies to not have wings, eliminating the ability of the flies to engage in the natural behavior of flight. This modification has not been deployed for adult black soldier flies - but flightless lines of fruit flies have been generated and are frequently sold as feeders for other animals.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.